Tennessee Medicaid spending on GLP-1 drugs

How much did Tennessee Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $144.1 million for GLP-1 drugs paid through Tennessee Medicaid in 2025, across at least 136,023 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 45 rows of 189, so these figures are floors.

Pharmacies were reimbursed at least $70.7 million for GLP-1 drugs paid through Tennessee Medicaid in 2026 (quarter 1 only, as posted so far), across at least 62,734 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 14 rows of 54, so these figures are floors.

By year and ingredient

2020at least $2,796,455No dataat least $12,488,496at least $3,602,324at least $6,917,678Suppressedat least $19,810$132,379at least $25,957,142
2021at least $8,443,145No data$15,415,818at least $8,262,182at least $7,106,019No data$117,158$161,280at least $39,505,603
2022at least $32,089,357at least $624,117$13,848,089at least $9,797,016at least $4,959,339Suppressed$184,590$81,362at least $61,583,871
2023at least $58,985,686at least $10,760,889at least $10,411,047at least $8,749,128at least $2,998,330No data$166,615at least $25,049at least $92,096,744
2024at least $64,184,019at least $17,604,142$3,186,154at least $3,725,327at least $1,458,696No data$59,804Suppressedat least $90,218,142
2025at least $92,969,821at least $47,036,220at least $1,477,842at least $2,374,516at least $197,595No data$48,069Suppressedat least $144,104,065
2026 (Q1)at least $39,315,107at least $30,703,370at least $197,340$438,225No dataNo data$8,148Suppressedat least $70,662,190

By product, 2025

Ozempicat least $56,614,243at least 58,1507 of 19
Rybelsus$1,887,2681,9430 of 12
Wegovy$34,468,31026,2360 of 20
Mounjaroat least $32,142,106at least 30,54014 of 38
Zepboundat least $14,894,114at least 14,03010 of 31
Liraglutide (generic name listing)at least $795,688at least 1,6055 of 26
Saxenda$506,6354580 of 4
Victoza$175,5192730 of 8
Trulicityat least $2,374,516at least 2,4812 of 18
Bydureonat least $197,595at least 2451 of 3
ByettaSuppressedSuppressed2 of 2
Soliqua$48,069620 of 4
XultophySuppressedSuppressed4 of 4

By quarter, 2025

Q1 2025at least $25,633,192at least 25,23014 of 48
Q2 2025at least $28,503,034at least 27,73510 of 45
Q3 2025at least $34,429,774at least 32,6457 of 44
Q4 2025at least $55,538,065at least 50,41314 of 52

By quarter, 2026 (posted so far)

Q1 2026at least $70,662,190at least 62,73414 of 54

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.